ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
After market 04:56:09 pm | |||
| 764 USD | +0.83% |
|
763.2 | -0.10% |
| 02:36pm | Argus Adjusts Price Target on Eli Lilly to $840 From $770 | MT |
| 01:33pm | Redburn Atlantic Adjusts Eli Lilly Price Target to $600 From $540 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
757.7
USD
Average target price
850.4
USD
Spread / Average Target
+12.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.06% | 682B | |
| +30.35% | 586B | |
| -3.42% | 364B | |
| +18.02% | 327B | |
| +4.27% | 285B | |
| +15.53% | 240B | |
| +10.16% | 209B | |
| -8.14% | 203B | |
| +8.12% | 165B | |
| -1.42% | 161B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Goldman Sachs Raises Price Target for Eli Lilly and Company to $234 From $231, Maintains Neutral Rating